Next Article in Journal / Special Issue
Targeted Therapy in Nonmelanoma Skin Cancers
Previous Article in Journal
Therapeutic Response in Patients with Advanced Malignancies Treated with Combined Dendritic Cell–Activated T Cell Based Immunotherapy and Intensity–Modulated Radiotherapy
Previous Article in Special Issue
Cell Autonomous and Non-Autonomous Functions of IKKβ and NF-κB during the Pathogenesis of Gastrointestinal Tumors
Cancers 2011, 3(2), 2243-2254; doi:10.3390/cancers3022243
Review

Targeted Therapy for Biliary Tract Cancer

1,*  and 2
Received: 4 March 2011; in revised form: 10 April 2011 / Accepted: 13 April 2011 / Published: 3 May 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
View Full-Text   |   Download PDF [229 KB, uploaded 3 May 2011]
Abstract: It is necessary to establish effective chemotherapy to improve the survival of patients with biliary tract cancer, because most of these patients are unsuitable candidates for surgery, and even patients undergoing curative surgery often have recurrence. Recently, the combination of cisplatin plus gemcitabine was reported to show survival benefits over gemcitabine alone in randomized clinical trials conducted in the United Kingdom and Japan. Thus, the combination of cisplatin plus gemcitabine is now recognized as the standard therapy for unresectable biliary tract cancer. One of the next issues that need to be addressed is whether molecular targeted agents might also be effective against biliary tract cancer. Although some targeted agents have been investigated as monotherapy for first-line chemotherapy, none were found to exert satisfactory efficacy. On the other hand, monoclonal antibodies such as bevacizumab and cetuximab have also been investigated in combination with a gemcitabine-based regimen and have been demonstrated to show promising activity. Furthermore, clinical trials using new targeted agents for biliary tract cancer are also proposed. This cancer is a relatively rare and heterogeneous tumor consisting of cholangiocarcinoma and gallbladder carcinoma. Therefore, a large randomized clinical trial is necessary to confirm the efficacy of chemotherapy, and international collaboration is important.
Keywords: biliary tract cancer; chemotherapy; molecular targeted agent biliary tract cancer; chemotherapy; molecular targeted agent
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Furuse, J.; Okusaka, T. Targeted Therapy for Biliary Tract Cancer. Cancers 2011, 3, 2243-2254.

AMA Style

Furuse J, Okusaka T. Targeted Therapy for Biliary Tract Cancer. Cancers. 2011; 3(2):2243-2254.

Chicago/Turabian Style

Furuse, Junji; Okusaka, Takuji. 2011. "Targeted Therapy for Biliary Tract Cancer." Cancers 3, no. 2: 2243-2254.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert